Market Research Report
HC 1119- Emerging Drug Insight and Market Forecast - 2030
|Published by||DelveInsight Business Research LLP||Product code||959711|
|Published||Content info||50 Pages
Delivery time: 1-2 business days
|HC 1119- Emerging Drug Insight and Market Forecast - 2030|
|Published: September 8, 2020||Content info: 50 Pages||
"HC 1119- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prostate cancer in 7 Major Markets. A detailed picture of the HC 1119 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
HC-1119 is the new molecluar entity which was disovered by Hinova. It is a small molecule antagonist of AR and being developed for the treatment of late-stage prostate cancers. An IND was approved by NMPA in 2016 and Phase I clinical trials were conducted in China. An IND with FDA filed in January, 2019 and approved for clinical studies in Feburay, 2019. The Phase III trial of international multi-enter is starting in US, China, EU, Australia, Canada, and Russia.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of HC 1119 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of HC 1119 covering trial interventions, trial conditions, trial status, start and completion dates.